{
    "id": 1626,
    "fullName": "KIT V559A",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "KIT V559A lies within the juxtamembrane domain (exon 11) of the Kit protein (PMID: 15837988). V559A results in constitutive phosphorylation of Kit and increased Mapk and Akt activation in patient samples and cultured cells (PMID: 15837988, PMID: 19047099).",
            "references": [
                {
                    "id": 649,
                    "pubMedId": 15837988,
                    "title": "Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15837988"
                },
                {
                    "id": 9825,
                    "pubMedId": 19047099,
                    "title": "Imatinib targeting of KIT-mutant oncoprotein in melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19047099"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3815,
        "geneSymbol": "KIT",
        "terms": [
            "KIT",
            "C-Kit",
            "CD117",
            "MASTC",
            "PBT",
            "SCFR"
        ]
    },
    "variant": "V559A",
    "createDate": "09/07/2014",
    "updateDate": "05/14/2019",
    "referenceTranscriptCoordinates": {
        "id": 136776,
        "transcript": "NM_000222",
        "gDna": "chr4:g.54727444T>C",
        "cDna": "c.1676T>C",
        "protein": "p.V559A",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11823,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Gleevec (imatinib) treatment in a patient with metastatic melanoma resulted in regression of the lung metastasis, which harbored KIT V559A; however, neither the primary tumor or lymph node metastasis responded, which had wild-type KIT (PMID: 19812602).",
            "molecularProfile": {
                "id": 1640,
                "profileName": "KIT V559A"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9862,
                    "pubMedId": 19812602,
                    "title": "Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19812602"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14622,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, KIT V559A was identified as a secondary mutation in a patient with gastrointestinal stromal tumor who developed resistance to Gleevec (imatinib) (PMID: 18488160).",
            "molecularProfile": {
                "id": 1640,
                "profileName": "KIT V559A"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9253,
                "name": "gastrointestinal stromal tumor",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7082,
                    "pubMedId": 18488160,
                    "title": "Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18488160"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11235,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41), including a melanoma patient harboring KIT V559A demonstrating a partial response and progression-free survival of 19.4 months and overall survival of 32.9 months (PMID: 28327988).",
            "molecularProfile": {
                "id": 1640,
                "profileName": "KIT V559A"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9177,
                    "pubMedId": 28327988,
                    "title": "Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28327988"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17525,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Inlyta (axitinib) inhibited KIT phosphorylation and proliferation of transformed cells expressing KIT V559A in culture (PMID: 31205508).",
            "molecularProfile": {
                "id": 1640,
                "profileName": "KIT V559A"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15597,
                    "pubMedId": 31205508,
                    "title": "Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31205508"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1640,
            "profileName": "KIT V559A",
            "profileTreatmentApproaches": [
                {
                    "id": 1982,
                    "name": "KIT Inhibitor",
                    "profileName": "KIT V559A"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 136776,
            "transcript": "NM_000222",
            "gDna": "chr4:g.54727444T>C",
            "cDna": "c.1676T>C",
            "protein": "p.V559A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 136777,
            "transcript": "XM_017008178",
            "gDna": "chr4:g.54727444T>C",
            "cDna": "c.1676T>C",
            "protein": "p.V559A",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}